WAVE Life Sciences (WVE) PT Lowered to $14 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts WVE Hot Sheet
Price: $3.65 +1.96%
Rating Summary:
21 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
21 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
RBC Capital analyst Luca Issi lowered the price target on WAVE Life Sciences (NASDAQ: WVE) to $14.00 (from $15.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- GlobalFoundries Inc. (GFS) PT Lowered to $50 at Jefferies
- Procore Technologies, Inc (PCOR) PT Raised to $68 at Mizuho
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
